Connect Sign In
Anti-C1q Antibody, IgG
Ordering Recommendation
Assess risk for lupus nephritis and global systemic lupus erythematosus (SLE) disease activity.
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Mon
Reported
1-15 days
New York DOH Approval Status
Specimen Required
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Refrigerated.
Urine or plasma. Contaminated, heat-inactivated, severely hemolyzed or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference Interval
| 0-19 Units | Negative |
| 20-39 Units | Equivocal |
| 40 Units or greater | Positive |
Interpretive Data
The presence of the anti-C1q IgG antibody may be associated with increased risk of lupus nephritis or with systemic lupus erythematosus (SLE) global activity. Anti-C1q antibodies are not specific for SLE; strong clinical correlation with disease is recommended.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Analyte Specific Reagent (ASR)
Note
Hotline History
CPT Codes
83516
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2007602 | Anti-C1q Antibody, IgG | 44702-9 |
Aliases
- C1q IgG Ab
Feedback
